Save time and get answers to complex questions with AI chat
Motegrity ingredients?Combivent generic equivalent?Zemdri nce gain exclusivity 2028 patent 2031?Campath litigation germany?Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?
See the DrugPatentWatch profile for gilenya
Gilenya (fingolimod) is taken once daily as a single oral capsule for relapsing forms of multiple sclerosis (MS) in adults and children aged 10 and older. The typical starting dose is 0.5 mg once per day, with titration only if needed for side effects like bradycardia.[1][2]
Patients continue one dose daily indefinitely, as long as benefits outweigh risks and under physician monitoring. No fixed number of total doses exists—it's ongoing therapy, often for years, with regular blood tests and cardiac checks before and after the first dose.[1][3]
Fingolimod binds to sphingosine-1-phosphate receptors, trapping lymphocytes in lymph nodes to reduce MS inflammation. Its 7-9 day half-life supports once-daily dosing without gaps.[3]
If pausing therapy, restart with observation due to rebound risks like worsened MS activity 2-3 months post-stop. Common switches go to alternatives like Ocrevus (infusion every 6 months) or oral Tecfidera (twice daily).[4][5]
Patients often ask about missed doses: take as soon as remembered unless near next dose—never double up. Pregnancy requires stopping 2 months prior due to fetal risks.[1][2] Sources [1]: Gilenya Prescribing Information (Novartis) [2]: FDA Label for Gilenya [3]: MS Society on Gilenya [4]: Drugs.com Gilenya Dosing [5]: DrugPatentWatch: Gilenya Patents
Other Questions About Gilenya :